A Field Study for the Evaluation of AIGIV Clinical Benefit and Safety in the Treatment of Patients With Inhalational Anthrax in a Broad Exposure Event Scenario
Status: Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Feb 2019
Price : $35 *
At a glance
- Drugs Anthrax immune globulin (Primary)
- Indications Anthrax
- Focus Therapeutic Use
- Sponsors Emergent BioSolutions
- 25 Jan 2019 Planned initiation date changed from 1 Aug 2018 to 1 Aug 2019.
- 02 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Aug 2018.
- 02 Jul 2018 New trial record